Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.64 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.58 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA5A | P35218 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 3/20 | 0.54 |
| ▸ | HTR2C | P28335 | 2/20 | 0.54 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | HTR6 | P50406 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 4/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21243265 | 0.90 | MPO (0.70) | MPOMTNR1AMTNR1BCA12CA1 | |
| SCHEMBL27593083 | 0.89 | MPO (0.66) | MPOBCHECHRM2GRIN1GRIN2A | |
| SCHEMBL15218669 | 0.84 | CA12 (0.60) | MPOCA12CA1CA2CA14 | |
| SCHEMBL24713016 | 0.84 | ALDH1A1 (0.55) | MPOHTR2A | |
| SCHEMBL7917106 | 0.82 | BCHE (0.62) | MPOMTNR1AMTNR1BTAAR1HTR2A | |
| SCHEMBL158584 | 0.82 | TAAR1 (0.67) | MTNR1AMTNR1BCA12CA1CA2 | |
| SCHEMBL29467401 | 0.82 | TAAR1 (0.67) | MTNR1AMTNR1BCA12CA1CA2 | |
| SCHEMBL3994288 | 0.82 | CHRM2 (0.67) | BCHECHRM2GRIN1GRIN2AACHE | |
| SCHEMBL681494 | 0.81 | MTNR1A (0.62) | MPOMTNR1AMTNR1BCA12CA1 | |
| SCHEMBL3130371 | 0.81 | CHRM2 (0.66) | BCHECHRM2GRIN1GRIN2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102050766-B | Synthesis method for amosulalol hydrochloride | ANHUI NEW STAR PHARMACEUTICAL DEV CO LTD | 2013-08-07 | — | — | CN | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| CN-102050766-A | Synthesis method for amosulalol hydrochloride | ANHUI NEW STAR PHARMACEUTICAL DEV CO LTD | 2011-05-11 | — | — | CN | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7504391-B2 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-7138533-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-21 | — | — | US | disclosed |
| US-7132547-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-07 | — | — | US | disclosed |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ISHIHARA YUJI | 2006-09-21 | — | — | US | disclosed |
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-23 | — | — | US | disclosed |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-08 | — | — | US | disclosed |
| EP-1466625-A1 | PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | MPO 354/4885MTNR1A 67/4885MTNR1B 97/4885 |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | MPO 354/4885MTNR1A 67/4885MTNR1B 97/4885 |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, ACE | MPO 246/4885MTNR1A 100/4885MTNR1B 129/4885 |
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | MPO 180/4885MTNR1A 2892/4885MTNR1B 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.